Head and neck pathology · 2025
Odontogenic Sarcomas: Clinicopathologic Analysis and Immunohistochemical Expression of BRAF and SOX9 in a Multicenter Series of 10 Cases.
СтатьяМногоцентровое исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Roza Ana Luiza Oliveira Corrêa, de Freitas Stephanie Vargas, Smit Chané, Rocha André Caroli, Agostini Michelle, Cortezzi Ellen Brilhante, Abrahão Aline Corrêa, Shumway Brian, Shrestha Madhu, Cabido Letícia Ferreira, Woo Victoria, Martínez-Rondanelli Benjamin, Mosqueda-Taylor Adalberto, van Heerden Willie F P, Wright John M, Vargas Pablo Agustin, Romañach Mário José
Аннотация
INTRODUCTION: Odontogenic sarcomas (OS) are rare malignant mixed odontogenic tumors featuring benign epithelial and malignant ectomesenchymal components.
MATERIALS AND METHODS: Ten OS cases from seven Oral and Maxillofacial Pathology services were retrospectively reviewed (2000-2024), including clinical, radiographic, histopathologic, and immunohistochemical data (BRAF p.V600E and SOX9).
RESULTS: Five female and five male patients, with a mean age of 30 years (range: 9-72 years), presented with mandibular tumors, all as aggressive, ill-defined radiolucencies. Eight patients reported a prior diagnosis of a benign mixed odontogenic tumor (mean interval: 3.6 years). Six patients underwent wide surgical resection; one experienced recurrence within two years and showed high-grade transformation. Histopathologic examination revealed benign odontogenic epithelium within malignant ectomesenchyme with hypercellularity, pleomorphism, and increased mitotic figures. Rare features included ghost cells, microcystic degeneration, vacuolated morphology, and high-grade transformation. BRAF p.V600E was positive in 60% of the mesenchymal component. SOX9 was diffusely expressed in both epithelial and mesenchymal components, with reduced staining in the case with high-grade transformation.
CONCLUSION: OS primarily affects young adults and often arises from pre-existing benign mixed odontogenic tumors. Despite variable histology, the biological behavior of the tumors remains consistently aggressive. BRAF p.V600E and SOX9 may aid diagnosis. Vigilant follow-up of patients diagnosed with benign mixed odontogenic tumors is essential, particularly within four years post-surgery. Multicenter studies are warranted to better understand the pathogenesis of OS and support the development of targeted therapeutic strategies.
MATERIALS AND METHODS: Ten OS cases from seven Oral and Maxillofacial Pathology services were retrospectively reviewed (2000-2024), including clinical, radiographic, histopathologic, and immunohistochemical data (BRAF p.V600E and SOX9).
RESULTS: Five female and five male patients, with a mean age of 30 years (range: 9-72 years), presented with mandibular tumors, all as aggressive, ill-defined radiolucencies. Eight patients reported a prior diagnosis of a benign mixed odontogenic tumor (mean interval: 3.6 years). Six patients underwent wide surgical resection; one experienced recurrence within two years and showed high-grade transformation. Histopathologic examination revealed benign odontogenic epithelium within malignant ectomesenchyme with hypercellularity, pleomorphism, and increased mitotic figures. Rare features included ghost cells, microcystic degeneration, vacuolated morphology, and high-grade transformation. BRAF p.V600E was positive in 60% of the mesenchymal component. SOX9 was diffusely expressed in both epithelial and mesenchymal components, with reduced staining in the case with high-grade transformation.
CONCLUSION: OS primarily affects young adults and often arises from pre-existing benign mixed odontogenic tumors. Despite variable histology, the biological behavior of the tumors remains consistently aggressive. BRAF p.V600E and SOX9 may aid diagnosis. Vigilant follow-up of patients diagnosed with benign mixed odontogenic tumors is essential, particularly within four years post-surgery. Multicenter studies are warranted to better understand the pathogenesis of OS and support the development of targeted therapeutic strategies.